BeiGene
BGNE
#971
Rank
NZ$35.78 B
Marketcap
$327.03
Share price
0.49%
Change (1 day)
23.78%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -NZ$1.42 Billion

According to BeiGene 's latest financial reports the company's current earnings are NZ$3.31 Billion. In 2023 the company made an earning of -NZ$2.14 Billion, an increase over its 2022 earnings that were of -NZ$3.17 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -NZ$1.42 Billion-34.05%
2023 -NZ$2.14 Billion-32.52%
2022 -NZ$3.17 Billion24.39%
2021 -NZ$2.55 Billion-13.21%
2020 -NZ$2.94 Billion72.69%
2019 -NZ$1.7 Billion36.01%
2018 -NZ$1.25 Billion616.83%
2017 -NZ$0.18 Billion-15.24%
2016 -NZ$0.21 Billion107.91%
2015 -NZ$98.93 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-NZ$32.15 Million-97.92%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$0.21 Billion-86.49%๐Ÿ‡บ๐Ÿ‡ธ USA